Craft

TME Pharma

Stock Price

€0.3

2024-03-22

Market Capitalization

€9.4 M

2024-03-22

TME Pharma Summary

Company Summary

Overview
TME Pharma (formerly known as NOXXON Pharma) is a clinical-stage biopharmaceutical company that focuses on the development of proprietary therapeutics for the treatment of cancer. It offers Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidates, NOX-A12 and NOX-E36, which are under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia.
Type
Public
Status
Active
Founded
1998
HQ
Berlin, DE | view all locations
Website
https://www.tmepharma.com/
Cybersecurity rating
Sectors

Key People

  • Aram Mangasarian

    Aram Mangasarian, CEO

    • Jarl Ulf Jungnelius

      Jarl Ulf Jungnelius, Chief Medical Officer

      LocationsView all

      1 location detected

      • Berlin, Berlin HQ

        Germany

        8 Max-Dohrn-Straße

      TME Pharma Financials

      Summary Financials

      Gross profit (FY, 2022)
      €34.0K
      Net income (FY, 2022)
      (€15.1M)
      Cash (FY, 2022)
      €4.6M
      EBIT (FY, 2022)
      (€12.0M)
      Enterprise value
      $8.7M

      Footer menu